B-Cellular_component	0	7	Nuclear	Nuclear	JJ	B-NP
O	8	21	translocation	translocation	NN	I-NP
O	22	24	of	of	IN	B-PP
O	25	26	a	a	DT	B-NP
O	27	36	clusterin	clusterin	NN	I-NP
O	37	44	isoform	isoform	NN	I-NP
O	45	47	is	be	VBZ	B-VP
O	48	58	associated	associate	VBN	I-VP
O	59	63	with	with	IN	B-PP
O	64	73	induction	induction	NN	B-NP
O	74	76	of	of	IN	B-PP
O	77	84	anoikis	anoikis	NN	B-NP
O	85	87	in	in	IN	B-PP
O	88	92	SV40	SV40	NN	B-NP
O	92	93	-	-	HYPH	O
O	93	105	immortalized	immortalize	VBN	B-NP
O	106	111	human	human	JJ	I-NP
B-Cell	112	120	prostate	prostate	NN	I-NP
I-Cell	121	131	epithelial	epithelial	JJ	I-NP
I-Cell	132	137	cells	cell	NNS	I-NP
O	137	138	.	.	.	O

O	140	149	Clusterin	Clusterin	NN	B-NP
O	150	154	gene	gene	NN	I-NP
O	155	165	expression	expression	NN	I-NP
O	166	168	is	be	VBZ	B-VP
O	169	177	potently	potently	RB	I-VP
O	178	185	induced	induce	VBN	I-VP
O	186	188	in	in	IN	B-PP
O	189	201	experimental	experimental	JJ	B-NP
O	202	208	models	model	NNS	I-NP
O	209	211	in	in	IN	B-PP
O	212	217	which	which	WDT	B-NP
O	218	227	apoptosis	apoptosis	NN	B-NP
O	228	230	is	be	VBZ	B-VP
O	231	240	activated	activate	VBN	I-VP
O	240	241	,	,	,	O
O	242	246	such	such	JJ	B-PP
O	247	249	as	as	IN	I-PP
O	250	253	rat	rat	NN	B-NP
B-Organ	254	262	prostate	prostate	NN	I-NP
O	263	273	involution	involution	NN	I-NP
O	274	283	following	follow	VBG	B-PP
O	284	294	castration	castration	NN	B-NP
O	294	295	.	.	.	O

O	296	308	Nevertheless	Nevertheless	RB	B-ADVP
O	308	309	,	,	,	O
O	310	313	its	its	PRP$	B-NP
O	314	321	precise	precise	JJ	I-NP
O	322	335	physiological	physiological	JJ	I-NP
O	336	340	role	role	NN	I-NP
O	341	344	has	have	VBZ	B-VP
O	345	348	not	not	RB	I-VP
O	349	352	yet	yet	RB	I-VP
O	353	357	been	be	VBN	I-VP
O	358	369	established	establish	VBN	I-VP
O	369	370	,	,	,	O
O	371	374	and	and	CC	O
O	375	379	both	both	DT	B-NP
O	380	384	anti	anti	AFX	O
O	384	385	-	-	HYPH	O
O	385	394	apoptotic	apoptotic	JJ	B-ADJP
O	395	398	and	and	CC	O
O	399	402	pro	pro	AFX	O
O	402	403	-	-	HYPH	O
O	403	412	apoptotic	apoptotic	JJ	B-NP
O	413	422	functions	function	NNS	I-NP
O	423	427	have	have	VBP	B-VP
O	428	432	been	be	VBN	I-VP
O	433	442	suggested	suggest	VBN	I-VP
O	443	446	for	for	IN	B-PP
O	447	451	this	this	DT	B-NP
O	452	456	gene	gene	NN	I-NP
O	456	457	.	.	.	O

O	458	467	Clusterin	Clusterin	NN	B-NP
O	468	478	expression	expression	NN	I-NP
O	479	484	level	level	NN	I-NP
O	485	492	depends	depend	VBZ	B-VP
O	493	495	on	on	IN	B-PP
B-Cell	496	500	cell	cell	NN	B-NP
O	501	514	proliferation	proliferation	NN	I-NP
O	515	520	state	state	NN	I-NP
O	520	521	,	,	,	O
O	522	525	and	and	CC	O
O	526	528	we	we	PRP	B-NP
O	529	537	recently	recently	RB	B-ADVP
O	538	544	showed	show	VBD	B-VP
O	545	549	that	that	IN	B-SBAR
O	550	553	its	its	PRP$	B-NP
O	554	558	over	over	AFX	I-NP
O	558	559	-	-	HYPH	I-NP
O	559	569	expression	expression	NN	I-NP
O	570	579	inhibited	inhibit	VBD	B-VP
B-Cell	580	584	cell	cell	NN	B-NP
O	585	590	cycle	cycle	NN	I-NP
O	591	602	progression	progression	NN	I-NP
O	603	605	of	of	IN	B-PP
O	606	610	SV40	SV40	NN	B-NP
O	610	611	-	-	HYPH	O
O	611	623	immortalized	immortalize	VBN	B-NP
O	624	629	human	human	JJ	I-NP
B-Cell	630	638	prostate	prostate	NN	I-NP
I-Cell	639	649	epithelial	epithelial	JJ	I-NP
I-Cell	650	655	cells	cell	NNS	I-NP
I-Cell	656	660	PNT2	PNT2	NN	I-NP
O	661	664	and	and	CC	I-NP
B-Cell	665	670	PNT1a	PNT1a	NN	I-NP
O	670	671	.	.	.	O

O	672	676	Here	Here	RB	B-ADVP
O	677	679	we	we	PRP	B-NP
O	680	687	studied	study	VBD	B-VP
O	688	697	clusterin	clusterin	NN	B-NP
O	698	708	expression	expression	NN	I-NP
O	709	711	in	in	IN	B-PP
B-Cell	712	717	PNT1a	PNT1a	NN	B-NP
I-Cell	718	723	cells	cell	NNS	I-NP
O	724	733	subjected	subject	VBN	B-VP
O	734	736	to	to	TO	B-PP
B-Organism_substance	737	742	serum	serum	NN	B-NP
O	742	743	-	-	HYPH	B-NP
O	743	753	starvation	starvation	NN	I-NP
O	754	758	with	with	IN	B-PP
O	759	762	the	the	DT	B-NP
O	763	766	aim	aim	NN	I-NP
O	767	769	of	of	IN	B-PP
O	770	778	defining	define	VBG	B-VP
O	779	788	clusterin	clusterin	NN	B-NP
O	789	794	early	early	JJ	I-NP
O	795	804	molecular	molecular	JJ	I-NP
O	805	812	changes	change	NNS	I-NP
O	813	822	following	follow	VBG	B-PP
O	823	832	apoptosis	apoptosis	NN	B-NP
O	833	842	induction	induction	NN	I-NP
O	842	843	.	.	.	O

O	844	849	Under	Under	IN	B-PP
B-Organism_substance	850	855	serum	serum	NN	B-NP
O	855	856	-	-	HYPH	B-NP
O	856	866	starvation	starvation	NN	I-NP
O	867	877	conditions	condition	NNS	I-NP
O	877	878	,	,	,	O
O	879	888	decreased	decrease	VBN	B-NP
O	889	895	growth	growth	NN	I-NP
O	896	900	rate	rate	NN	I-NP
O	900	901	,	,	,	O
O	902	906	slow	slow	JJ	B-NP
O	907	915	rounding	rounding	NN	I-NP
O	915	916	-	-	HYPH	B-VP
O	916	918	up	up	RP	B-PRT
O	919	921	of	of	IN	B-PP
B-Cell	922	927	cells	cell	NNS	B-NP
O	927	928	,	,	,	O
B-Cell	929	933	cell	cell	NN	B-NP
O	934	944	detachment	detachment	NN	I-NP
O	944	945	,	,	,	O
O	946	949	and	and	CC	O
O	950	959	formation	formation	NN	B-NP
O	960	962	of	of	IN	B-PP
B-Cellular_component	963	972	apoptotic	apoptotic	JJ	B-NP
I-Cellular_component	973	979	bodies	body	NNS	I-NP
O	980	990	indicative	indicative	JJ	B-ADJP
O	991	993	of	of	IN	B-PP
O	994	1001	anoikis	anoikis	NN	B-NP
O	1002	1003	(	(	(	O
O	1003	1013	detachment	detachment	NN	B-NP
O	1013	1014	-	-	HYPH	B-NP
O	1014	1021	induced	induce	VBN	I-NP
O	1022	1031	apoptosis	apoptosis	NN	I-NP
O	1031	1032	)	)	)	O
O	1033	1037	were	be	VBD	B-VP
O	1038	1046	preceded	precede	VBN	I-VP
O	1047	1049	by	by	IN	B-PP
O	1050	1061	significant	significant	JJ	B-NP
O	1062	1076	downregulation	downregulation	NN	I-NP
O	1077	1079	of	of	IN	B-PP
O	1080	1082	70	70	CD	B-NP
O	1083	1086	kDa	kDa	NN	I-NP
O	1087	1096	clusterin	clusterin	NN	I-NP
O	1097	1106	precursor	precursor	NN	I-NP
O	1107	1110	and	and	CC	I-NP
O	1111	1123	upregulation	upregulation	NN	I-NP
O	1124	1126	of	of	IN	B-PP
O	1127	1129	45	45	CD	B-NP
O	1129	1130	-	-	HYPH	I-NP
O	1130	1132	40	40	CD	I-NP
O	1133	1136	kDa	kDa	NN	I-NP
O	1137	1145	isoforms	isoform	NNS	I-NP
O	1145	1146	.	.	.	O

O	1147	1149	On	On	IN	B-PP
O	1150	1153	the	the	DT	B-NP
O	1154	1157	8th	8th	JJ	I-NP
O	1158	1161	day	day	NN	I-NP
O	1162	1164	of	of	IN	B-PP
B-Organism_substance	1165	1170	serum	serum	NN	B-NP
O	1170	1171	-	-	HYPH	B-NP
O	1171	1175	free	free	JJ	I-NP
O	1176	1185	culturing	culturing	NN	I-NP
O	1185	1186	,	,	,	O
O	1187	1191	only	only	RB	B-NP
O	1192	1195	the	the	DT	I-NP
O	1196	1202	higher	high	JJR	I-NP
O	1203	1212	molecular	molecular	JJ	I-NP
O	1213	1219	weight	weight	NN	I-NP
O	1220	1227	protein	protein	NN	I-NP
O	1227	1228	-	-	HYPH	B-NP
O	1228	1232	band	band	NN	I-NP
O	1233	1235	of	of	IN	B-PP
O	1236	1241	about	about	RB	B-NP
O	1242	1244	45	45	CD	I-NP
O	1245	1248	kDa	kDa	NN	I-NP
O	1249	1252	was	be	VBD	B-VP
O	1253	1260	clearly	clearly	RB	I-VP
O	1261	1268	induced	induce	VBN	I-VP
O	1269	1272	and	and	CC	I-VP
O	1273	1284	accumulated	accumulate	VBN	I-VP
O	1285	1287	in	in	IN	B-PP
O	1288	1296	detached	detach	VBN	B-NP
B-Cell	1297	1302	cells	cell	NNS	I-NP
O	1303	1306	and	and	CC	O
B-Cellular_component	1307	1316	apoptotic	apoptotic	JJ	B-NP
I-Cellular_component	1317	1323	bodies	body	NNS	I-NP
O	1324	1326	in	in	IN	B-PP
O	1327	1332	which	which	WDT	B-NP
O	1333	1337	PARP	PARP	NN	B-NP
O	1338	1341	was	be	VBD	B-VP
O	1342	1351	activated	activate	VBN	I-VP
O	1351	1352	.	.	.	O

O	1353	1360	Anoikis	Anoikis	NNP	B-NP
O	1361	1364	was	be	VBD	B-VP
O	1365	1373	preceded	precede	VBN	I-VP
O	1374	1376	by	by	IN	B-PP
O	1377	1386	induction	induction	NN	B-NP
O	1387	1390	and	and	CC	I-NP
O	1391	1403	transloction	transloction	NN	I-NP
O	1404	1406	of	of	IN	B-PP
O	1407	1408	a	a	DT	B-NP
O	1409	1411	45	45	CD	I-NP
O	1411	1412	-	-	HYPH	I-NP
O	1412	1415	kDa	kDa	NN	I-NP
O	1416	1425	clusterin	clusterin	NN	I-NP
O	1426	1433	isoform	isoform	NN	I-NP
O	1434	1436	to	to	TO	B-PP
O	1437	1440	the	the	DT	B-NP
B-Cellular_component	1441	1448	nucleus	nucleus	NN	I-NP
O	1448	1449	.	.	.	O

O	1450	1454	Thus	Thus	RB	B-ADVP
O	1454	1455	,	,	,	O
B-Cellular_component	1456	1463	nuclear	nuclear	JJ	B-NP
O	1464	1473	targeting	targeting	NN	I-NP
O	1474	1476	of	of	IN	B-PP
O	1477	1478	a	a	DT	B-NP
O	1479	1487	specific	specific	JJ	I-NP
O	1488	1490	45	45	CD	I-NP
O	1490	1491	-	-	HYPH	I-NP
O	1491	1494	kDa	kDa	NN	I-NP
O	1495	1502	isoform	isoform	NN	I-NP
O	1503	1505	of	of	IN	B-PP
O	1506	1515	clusterin	clusterin	NN	B-NP
O	1516	1524	appeared	appear	VBD	B-VP
O	1525	1527	to	to	TO	I-VP
O	1528	1530	be	be	VB	I-VP
O	1531	1533	an	an	DT	B-NP
O	1534	1539	early	early	JJ	I-NP
O	1540	1543	and	and	CC	I-NP
O	1544	1552	specific	specific	JJ	I-NP
O	1553	1562	molecular	molecular	JJ	I-NP
O	1563	1569	signal	signal	NN	I-NP
O	1570	1580	triggering	trigger	VBG	B-VP
O	1581	1588	anoikis	anoikis	NN	B-NP
O	1588	1589	-	-	HYPH	I-NP
O	1589	1594	death	death	NN	I-NP
O	1594	1595	.	.	.	O

O	1596	1607	Considering	Consider	VBG	B-VP
O	1608	1612	also	also	RB	B-ADVP
O	1613	1617	that	that	IN	B-SBAR
O	1618	1627	clusterin	clusterin	NN	B-NP
O	1628	1630	is	be	VBZ	B-VP
O	1631	1644	downregulated	downregulate	VBN	I-VP
O	1645	1651	during	during	IN	B-PP
B-Cancer	1652	1660	prostate	prostate	NN	B-NP
I-Cancer	1661	1667	cancer	cancer	NN	I-NP
O	1668	1673	onset	onset	NN	I-NP
O	1674	1677	and	and	CC	I-NP
O	1678	1689	progression	progression	NN	I-NP
O	1689	1690	,	,	,	O
O	1691	1694	and	and	CC	O
O	1695	1699	that	that	IN	B-SBAR
O	1700	1703	its	its	PRP$	B-NP
O	1704	1716	upregulation	upregulation	NN	I-NP
O	1717	1720	has	have	VBZ	B-VP
O	1721	1730	inhibited	inhibit	VBN	I-VP
O	1731	1734	DNA	DNA	NN	B-NP
O	1735	1744	synthesis	synthesis	NN	I-NP
O	1745	1748	and	and	CC	O
B-Cell	1749	1753	cell	cell	NN	B-NP
O	1754	1759	cycle	cycle	NN	I-NP
O	1760	1771	progression	progression	NN	I-NP
O	1772	1774	of	of	IN	B-PP
O	1775	1787	immortalized	immortalize	VBN	B-NP
O	1788	1793	human	human	JJ	I-NP
B-Cell	1794	1802	prostate	prostate	NN	I-NP
I-Cell	1803	1813	epithelial	epithelial	JJ	I-NP
I-Cell	1814	1819	cells	cell	NNS	I-NP
O	1819	1820	,	,	,	O
O	1821	1823	we	we	PRP	B-NP
O	1824	1831	suggest	suggest	VBP	B-VP
O	1832	1836	that	that	IN	B-SBAR
O	1837	1846	clusterin	clusterin	NN	B-NP
O	1847	1852	might	might	MD	B-VP
O	1853	1855	be	be	VB	I-VP
O	1856	1857	a	a	DT	B-NP
O	1858	1861	new	new	JJ	I-NP
O	1862	1866	anti	anti	AFX	I-NP
O	1866	1867	-	-	HYPH	I-NP
O	1867	1875	oncogene	oncogene	NN	I-NP
O	1876	1878	in	in	IN	B-PP
O	1879	1882	the	the	DT	B-NP
B-Organ	1883	1891	prostate	prostate	NN	I-NP
O	1891	1892	.	.	.	O

